Claire Bal dit Sollier, Isabelle Crassard, Guy G. Simoneau, Jean‐François Bergmann, Marie‐Germaine Bousser, Ludovic Drouet,
... i> The antithrombotic, antiplatelet and endothelial activity of terutroban, a specific thromboxane prostaglandin receptor antagonist, was assessed ... event and/or carotid stenosis in 4 groups: terutroban 10 mg/day (n = 13), aspirin 300 mg/day (n = 12), terutroban 10 mg/day + aspirin 300 mg/day (n = ... sectional surface of dense thrombus significantly decreased with terutroban (58%, p = 0.001), terutroban + aspirin (63%, p = 0.005) and clopidogrel + aspirin ( ... 0.05). On day 10, the value for terutroban was significantly lower than that for aspirin (p < ...
Tópico(s): Venous Thromboembolism Diagnosis and Management
2009 - Karger Publishers | Cerebrovascular Diseases
Paolo Gelosa, Rossana Ballerio, Cristina Banfi, Elena Nobili, Anita Gianella, Alice Pignieri, Maura Brioschi, Uliano Guerrini, Laura Castiglioni, Vanessa Blanc‐Guillemaud, L. Lerond, Elena Tremoli, Luigi Sironi,
This study investigated the efficacy of terutroban, a specific thromboxane/prostaglandin endoperoxide receptor antagonist, on stroke incidence in spontaneously hypertensive stroke-prone rats (SHRSP). The effects of terutroban were compared with those of aspirin, another antiplatelet ... were treated orally once a day with vehicle, terutroban (30 mg/kg/day), aspirin (60 mg/kg/ ... blood pressure or serum thromboxane B 2 levels, terutroban significantly increased survival ( p < 0.001) as a ... a delayed increase of proteinuria ( p < 0.001). Terutroban decreased cerebral mRNA transcription of interleukin-1β, transforming ...
Tópico(s): S100 Proteins and Annexins
2010 - American Society for Pharmacology and Experimental Therapeutics | Journal of Pharmacology and Experimental Therapeutics
J N Fiessinger, Henri Bounameaux, Marc Cairols, D Clément, S Coccheri, John Fletcher, Ulrike Hoffmann, A. G. G. Turpie,
SummaryBackground: Terutroban is a selective prostaglandin endoperoxide (TP) receptor antagonist with antithrombotic, antivasoconstrictive and antiatherosclerotic properties and is currently ... comparing the effects of five dosages of oral terutroban vs. aspirin and placebo on platelet aggregation in ... randomly allocated to aspirin 75 mg day−1, terutroban 1, 2.5, 5, 10 or 30 mg ... placebo group was reallocated to one of the terutroban groups for the rest of the study (day ... by arachidonic acid (AA), collagen and ADP. Results: Terutroban dose‐dependently inhibited U46619‐induced platelet aggregation at ...
Tópico(s): Venous Thromboembolism Diagnosis and Management
2010 - Elsevier BV | Journal of Thrombosis and Haemostasis
Jeffrey I. Weitz, John W. Eikelboom, M Samama,
... Scholar Single-dose administration of 10 mg of terutroban to 12 patients with coronary artery disease who ... Google Scholar In patients with PAD randomized to terutroban, aspirin, or placebo, terutroban produced dose-dependent inhibition of platelet aggregation in ... MA TAIPAD investigators et al.Thromboxane antagonism with terutroban in peripheral arterial disease. The TAIPAD study.J ... Cerebrovascular and Cardiovascular Events of Ischemic Origin with Terutroban in Patients with a History of Ischemic Stroke ...
Tópico(s): Atrial Fibrillation Management and Outcomes
2012 - Elsevier BV | CHEST Journal
Valérie Capra, Magnus Bäck, Dominick J. Angiolillo, Marco Cattaneo, Kjell S. Sakaríassen,
... including sulotroban, daltroban, ifetroban, ramatroban, linotroban, seratrodast, and terutroban, have been developed and studied in various phases ... and clinical investigations (Table 1) 39. Among these, terutroban has been most broadly studied. Terutroban is an orally active TP receptor antagonist with ... model, 100 μg kg−1 day−1 of terutroban showed antithrombotic effects similar to the purinergic P2Y12 ... clopidogrel 13. Antithrombotic effects of escalating doses of terutroban have also been shown in patients with peripheral ...
Tópico(s): Nitric Oxide and Endothelin Effects
2013 - Elsevier BV | Journal of Thrombosis and Haemostasis
Pierre‐François Lesault, Laurent Boyer, Gabriel Pelle, Ala Covali‐Noroc, Dominique Rideau, Servais Akakpo, Emmanuel Teíger, Jean‐Luc Dubois‐Randé, Serge Adnot,
• Terutroban is a selective TP receptor antagonist, i.e. a specific antagonist of the thromboxane A(2) ... blind, placebo-controlled trial demonstrates that repeated-dose terutroban for 15 days improves endothelial function and inhibits ... patients taking 300 mg of aspirin per day. Terutroban may prove useful for preventing cardiovascular events in such patients.The specific TP receptor antagonist terutroban improves endothelial function after a single dose in ... the effects and dose dependency of repeated-dose terutroban on endothelial function and platelet aggregation in high- ...
Tópico(s): Nitric Oxide and Endothelin Effects
2010 - Wiley | British Journal of Clinical Pharmacology
Marie‐Germaine Bousser, Pierre Amarenco, Ángel Chamorro, Marc Fisher, Ian Ford, Kim Fox, Michael G. Hennerici, Heinrich P. Mattle, Peter M. Rothwell, Agnès de Cordoüe, Marie-Dominique Fratacci,
... We compared the selective thromboxane-prostaglandin receptor antagonist terutroban with aspirin in the prevention of cerebral and ... interactive response system to 30 mg per day terutroban or 100 mg per day aspirin. Patients and ... registered, number ISRCTN66157730.9562 patients were assigned to terutroban (9556 analysed) and 9558 to aspirin (9544 analysed); ... primary endpoint occurred in 1091 (11%) patients receiving terutroban and 1062 (11%) receiving aspirin (hazard ratio [HR] ... There was no evidence of a difference between terutroban and aspirin for the secondary or tertiary endpoints. ...
Tópico(s): Acute Ischemic Stroke Management
2011 - Elsevier BV | The Lancet
Eugenio Rosado, Aina Rodríguez–Vilarrupla, Jordi Gracia‐Sancho, Dinesh Mani Tripathi, Héctor García‐Calderó, Jaume Bosch, Juan Carlos García–Pagán,
... prostaglandin-endoperoxide (TP) receptor. This study investigated whether terutroban, a specific TP receptor blocker, decreases hepatic vascular ... in CCl4 and BDL cirrhotic rats treated with terutroban (30 mg/kg/day) or its vehicle for 2 weeks. Terutroban reduced portal pressure in both models without producing ... flow, suggesting a reduction in hepatic vascular resistance. Terutroban did not significantly change arterial pressure in CCl4 - ... rats. In livers from CCl4 and BDL-cirrhotic terutroban-treated rats, endothelial dysfunction was improved and Rho- ...
Tópico(s): Eicosanoids and Hypertension Pharmacology
2013 - Lippincott Williams & Wilkins | Hepatology
Paolo Gelosa, Gülnur Sevin, Alice Pignieri, Silvia Budelli, Laura Castiglioni, Vanessa Blanc‐Guillemaud, L. Lerond, Elena Tremoli, Luigi Sironi,
... the thromboxane/prostaglandin endoperoxide receptors. The effects of terutroban, a thromboxane/prostaglandin endoperoxide receptor antagonist, on aorta ... permissive diet plus vehicle (n = 6) or plus terutroban (30 mg · kg(-1) · day(-1); n = 6). ... with the rats fed a standard diet, whereas terutroban treatment completely prevented media thickening (P < 0.001). When compared with vehicle, terutroban was also effective in preventing cell proliferation in ... P < 0.01) but was completely prevented by terutroban (P < 0.001). The latter also inhibited heat ...
Tópico(s): Clinical practice guidelines implementation
2010 - American Physical Society | AJP Heart and Circulatory Physiology
Marie‐Germaine Bousser, Pierre Amarenco, Ángel Chamorro, Marc Fisher, Ian Ford, Kim Fox, Michael G. Hennerici, Heinrich P. Mattle, Peter M. Rothwell,
... a major contributor to neurological disability and dementia. Terutroban is a specific TP receptor antagonist with antithrombotic, ... cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke ... to demonstrate the superiority of the efficacy of terutroban versus aspirin in secondary prevention of cerebrovascular and ... or =8 days). Participants are randomly allocated to terutroban (30 mg/day) or aspirin (100 mg/day). ... Study will explore the benefits and safety of terutroban in secondary cardiovascular prevention after a cerebral ischemic ...
Tópico(s): Venous Thromboembolism Diagnosis and Management
2009 - Karger Publishers | Cerebrovascular Diseases
Michiel L. Bots, Ian Ford, Suzanne M. Lloyd, Stéphane Laurent, Pierre Touboul, Michael G. Hennerici,
... involved in the atherosclerotic process. We assessed whether Terutroban, a thromboxane prostaglandin receptor antagonist, affects the progression ... Cerebrovascular and Cardiovascular Events of Ischemic Origin with Terutroban in Patients with a History of Ischemic Stroke ... period. Results— Baseline characteristics did not differ between Terutroban (n=592) and aspirin (n=549) treated patients ... similar (28 and 25 months, respectively). In the Terutroban group, the annualized rate of change in common ... At 12 months of follow-up, 66% of Terutroban patients had no emergent plaques, 31% had 1 ...
Tópico(s): Acute Ischemic Stroke Management
2014 - Lippincott Williams & Wilkins | Stroke
... a major contributor to neurological disability and dementia. Terutroban is a specific thromboxane A<sub>2</sub> ... Cerebrovascular and Cardiovascular Events of Ischemic Origin with Terutroban in Patients with a History of Ischemic Stroke ... nonischemic neurological diseases. Patients are randomly allocated to terutroban (30 mg/day) or aspirin (100 mg/day). ... The PERFORM Study will explore the benefits of terutroban in secondary prevention of ischemic stroke. The study ...
Tópico(s): Antiplatelet Therapy and Cardiovascular Diseases
2009 - Karger Publishers | Cerebrovascular Diseases
... data have suggested that the antiplatelet activity of terutroban (an oral selective antagonist of thromboxane-prostaglandin receptors) ... of aspirin, with additional beneficial pleiotropic vascular effects. Terutroban versus aspirin in patients with cerebral ischaemic events ( ... showed similar rates of the primary endpoint with terutroban and aspirin, without safety advantages for terutroban. In a worldwide perspective, aspirin remains the gold ...
Tópico(s): Venous Thromboembolism Diagnosis and Management
2011 - Elsevier BV | The Lancet
... formation. The effect of the TP-receptor antagonist terutroban (S 18886) on different thrombosis models has been ... ApoE-/- and the LDL receptor-/- mice. Studies with terutroban have illustrated that this TP-receptor antagonist prevents ... anti-atherosclerotic properties of new substances such as terutroban, that may become novel treatments for this complex ... de thrombose, l’antagoniste des TP-récepteurs, le terutroban (S 18886) a démontré son efficacité indiquant donc ... les souris ApoE-/- et les souris LDLR-/-. Le terutroban a montré son efficacité dans différents modèles d’ ...
Tópico(s): Lipoproteins and Cardiovascular Health
2006 - Elsevier BV | Therapies
Marie‐Germaine Bousser, Pierre Amarenco, Ángel Chamorro, Marc Fisher, Ian Ford, Keith A.A. Fox, Michael G. Hennerici, Heinrich P. Mattle, Peter M. Rothwell,
... cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke ... the superiority of the specific TP receptor antagonist terutroban (30 mg/day) over aspirin (100 mg/day), ... study is powered to test the superiority of terutroban over aspirin in the secondary prevention of cerebrovascular ...
Tópico(s): Acute Ischemic Stroke Management
2009 - Karger Publishers | Cerebrovascular Diseases
Michael G. Hennerici, Michiel L. Bots, Ian Ford, Stéphane Laurent, Pierre‐Jean Touboul,
PERFORM is exploring the efficacy of terutroban versus aspirin for secondary prevention in patients with a history of ischemic stroke or transient ischemic attacks (TIAs). The PERFORM Vascular Project will evaluate the effect of terutroban on progression of atherosclerosis, as assessed by change ... April 2006. The PERFORM Vascular Project will investigate terutroban's effect on vascular structure and function in ...
Tópico(s): Cerebrovascular and Carotid Artery Diseases
2010 - Springer Science+Business Media | Cardiovascular Drugs and Therapy
... un puissant vasoconstricteur également activateur des plaquettes. Le terutroban (S 18886), quant à lui, agit plus spécifiquement ... Les études précliniques et cliniques effectuées avec le terutroban ont démontré ses effets antithrombotiques. Le but de ... de decrier les études qui, menées avec le terutroban, ont contribué à établir ce rôle. En effet, ...
Tópico(s): Nitric Oxide and Endothelin Effects
2006 - EDP Sciences | médecine/sciences
J.P. De La Cruz, Nuria Jebrouni, Juan Antonio López-Villodres, Javier Muñoz-Marín, A. Guerrero, José Antonio González Correa,
... present study is to investigate the effectiveness of terutroban, a selective antagonist of the thromboxane/prostaglandin endoperoxide ... kg/day p.o.), (4) DR treated with terutroban (5 mg/kg/day p.o.), (5) DR treated with terutroban (30 mg/kg/day p.o.). The follow- ... 3-nitrotyrosine. When compared with vehicle-treated DR, terutroban increased the percentage of retinal surface covered by PVPP (38% for terutroban-5 and 61% for terutroban-30), aortic prostacyclin (188% for terutroban-5 and 146% for terutroban-30) and nitric ...
Tópico(s): Antiplatelet Therapy and Cardiovascular Diseases
2011 - Wiley | Diabetes/Metabolism Research and Reviews
... receptors on vascular cells or in the plaque. Terutroban (Triplion® or S18886), a new oral specific TP ... an antiatherosclerotic effect. The potential therapeutic applications of terutroban in the prevention of atherothrombosis, particularly in the ... is currently comparing the efficacy and safety of terutroban versus aspirin in secondary prevention of cardiovascular events ...
Tópico(s): Lipoproteins and Cardiovascular Health
2009 - Karger Publishers | Cerebrovascular Diseases
Larry B. Goldstein, Peter M. Rothwell,
... trial compared the selective thromboxane-prostaglandin receptor antagonist terutroban with aspirin in patients with recent transient ischemic ... point occurring in 11% of subjects receiving either terutroban or aspirin (hazard ratio, 1.02; 95% CI, ... Fisher M, Ford I, Fox KM, et al. Terutroban versus aspirin in patients with cerebral ischaemic events ( ...
Tópico(s): Atrial Fibrillation Management and Outcomes
2012 - Lippincott Williams & Wilkins | Stroke
Marc K. Halushka, Perry V. Halushka,
... 2011) Daily administration of the TP receptor antagonist terutroban improved endothelial function in high-cardiovascular-risk patients ... Lerond L, Tremoli E and Sironi L (2011) Terutroban, a thromboxane/prostaglandin endoperoxide receptor antagonist, prevents hypertensive ...
Tópico(s): Venous Thromboembolism Diagnosis and Management
2002 - Lippincott Williams & Wilkins | Circulation
José W. van der Hoorn, J. Wouter Jukema, Marian Bekkers, P. Hans, Stefano Corda, Jeff J. Emeis, Paul Steendijk,
... combined treatment with thromboxane prostanoid-receptor antagonist S18886 (terutroban).
Tópico(s): Antiplatelet Therapy and Cardiovascular Diseases
2008 - Lippincott Williams & Wilkins | Critical Care Medicine
Giovanni Davı̀, Francesca Santilli, Natale Vazzana,
... leading to extraplatelet sources of TXA2. Among TXRA, terutroban is an orally active drug in clinical development ... PERFORM trial failed to demonstrate the superiority of terutroban over aspirin in secondary prevention of cerebrovascular and ...
Tópico(s): Venous Thromboembolism Diagnosis and Management
2012 - Springer Science+Business Media | Handbook of experimental pharmacology
Suzanne A. Nasser, Ahmed El‐Mallah, Ramzi Sabra, Mohamed M. Khedr, Mahmoud M. Mohy El‐Din, Mahmoud M. El‐Mas,
... selective ETA blocker, 10mg/kg/day), but not terutroban (thromboxane receptor blocker, 10mg/kg/day). Moreover, atrasentan ... protein expression of eNOS caused by CSA whereas terutroban was without effect. We also report that the ...
Tópico(s): Neuroscience of respiration and sleep
2014 - Elsevier BV | European Journal of Pharmacology
Wuxiang Xie, Fanfan Zheng, Bao‐Liang Zhong, Xiaoyu Song,
... significantly reduced intracranial hemorrhage compared with aspirin, clopidogrel, terutroban, ticlopidine, aspirin plus clopidogrel, and aspirin plus dipyridamole. ... significantly more major bleeding than all monotherapies except terutroban. The pooled estimates did not change materially in ...
Tópico(s): Atrial Fibrillation Management and Outcomes
2015 - Wiley | Journal of the American Heart Association
David Lagier, David Tonon, Philippe Garrigue, Benjamin Guillet, Laura Giacomino, Jean‐Charles Martin, Marie‐Christine Alessi, Nicolas Bruder, Lionel Velly,
... receptors, causing vasoconstriction and inflammation. Here, we evaluated terutroban (TBN), a specific TP receptor antagonist, for the ...
Tópico(s): Neurosurgical Procedures and Complications
2019 - BioMed Central | Critical Care
Yasser H. Habib, Sherien A. Abdelhady, Mennatallah A. Gowayed, Nevine M. El-Deeb, Inas E. Darwish, Mahmoud M. El‐Mas,
... ETA receptor blocker, 10 mg/kg/day) or terutroban (TXA2 receptor blocker, 10 mg/kg/day) on ... prototypic therapy for PE management. Among all drugs, terutroban was basically the most potent in ameliorating PE- ... with atrasentan and to a lesser extent by terutroban or α-MD. Atrasentan was also the most ... improves PE-evoked cardiovascular/renal anomalies. • Atrasentan or terutroban effects against PE overtake those of α-methyldopa.
Tópico(s): Maternal and fetal healthcare
2021 - Elsevier BV | Toxicology and Applied Pharmacology
Anna M. Maj, Isabelle Suisse, Nathalie Pinault, Francine Agbossou‐Niedercorn,
... key intermediate of the biologically active form of terutroban has been prepared by asymmetric hydrogenation. The catalysts ... R) correspondant à la forme biologiquement active du térutroban a été préparé par hydrogénation asymétrique. Les catalyseurs ...
Tópico(s): Chemical Synthesis and Analysis
2014 - Elsevier BV | Comptes Rendus Chimie
Nicolas Couvrat, Yohann Cartigny, Julie Linol, Lucile Vaysse‐Ludot, Pascal L. Langlois, Gérard Coquerel,
Terutroban sodium salt (Teru-Na) is a solid active pharmaceutical ingredient initially produced in its anhydrous form. ...
Tópico(s): Analytical Chemistry and Chromatography
2015 - Wiley | Chemical Engineering & Technology
Stephen J. Lewis, Andrew M. Allen, Anthony J.M. Verberne, R. Figdor, Bevyn Jarrott, Frederick A.O. Mendelsohn,
... BQ788). By contrast, the blockade of thromboxane receptors (terutroban) failed to alter the CSA-evoked facilitation of ...
Tópico(s): Pituitary Gland Disorders and Treatments
1986 - Elsevier BV | European Journal of Pharmacology